title: Changes in the expression of pituitary adenylate cyclase-activating polypeptide in the human placenta during pregnancy and its effects on the survival of JAR choriocarcinoma cells.
abstract: Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide with survival-promoting actions, has been observed in endocrine organs and is thought to play a role in reproductive functions, including pregnancy. PACAP occurs in two forms, 27 and 38 amino acid residues, with PACAP38 being the predominant form in human tissues. In the present study, we determined the concentrations of PACAP38 and PACAP27 in first-trimester and full-term human placentas using radioimmunoassay. We found high levels of PACAP38 and lower levels of PACAP27 in different parts of the full-term human placenta. PACAP38 content increased in the placenta during pregnancy, both on the maternal side and on the fetal side. The effects of PACAP on the survival of JAR human choriocarcinoma cells were investigated using flow cytometry and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) cell viability assay in cells exposed to the widely used chemotherapeutic agent methotrexate (MTX). It was found that PACAP neither influenced the survival of JAR cytotrophoblast cells nor affected cellular response to the death-inducing effect of the chemotherapeutic agent MTX. The present observations further support the significance of PACAP in the human placenta. The observation that PACAP did not influence the effects of MTX may have future clinical importance, showing that PACAP does not decrease the effects of certain chemotherapeutic agents.
authors.affiliation: Department of Anatomy, University of Pecs, Szigeti u 12, Pecs, Hungary.
authors.forename: R
authors.initials: R
authors.lastname: Brubel
authors.forename: A
authors.initials: A
authors.lastname: Boronkai
authors.forename: D
authors.initials: D
authors.lastname: Reglodi
authors.forename: B
authors.initials: B
authors.lastname: Racz
authors.forename: J
authors.initials: J
authors.lastname: Nemeth
authors.forename: P
authors.initials: P
authors.lastname: Kiss
authors.forename: A
authors.initials: A
authors.lastname: Lubics
authors.forename: G
authors.initials: G
authors.lastname: Toth
authors.forename: G
authors.initials: G
authors.lastname: Horvath
authors.forename: T
authors.initials: T
authors.lastname: Varga
authors.forename: D
authors.initials: D
authors.lastname: Szogyi
authors.forename: E
authors.initials: E
authors.lastname: Fonagy
authors.forename: J
authors.initials: J
authors.lastname: Farkas
authors.forename: A
authors.initials: A
authors.lastname: Barakonyi
authors.forename: Sz
authors.initials: S
authors.lastname: Bellyei
authors.forename: L
authors.initials: L
authors.lastname: Szereday
authors.forename: M
authors.initials: M
authors.lastname: Koppan
authors.forename: A
authors.initials: A
authors.lastname: Tamas
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D002822:Choriocarcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000378:metabolism* / Q000494:pharmacology*; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D020033:Protein Isoforms / Q000378:metabolism / Q000494:pharmacology; D011863:Radioimmunoassay; D011897:Random Allocation
chemical_list: D007166:Immunosuppressive Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D020033:Protein Isoforms; D008727:Methotrexate
references.citation: Br J Cancer. 2005 Apr 25;92(8):1506-16
references.pmid: 15846300
references.citation: Endocrinology. 1991 Nov;129(5):2787-9
references.pmid: 1935809
references.citation: Endocrinology. 2003 Apr;144(4):1631-43
references.pmid: 12639948
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):270-8
references.pmid: 18607779
references.citation: Regul Pept. 1996 Mar 22;61(3):197-204
references.pmid: 8701036
references.citation: Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74
references.pmid: 2803320
references.citation: Mol Reprod Dev. 2003 Jan;64(1):27-31
references.pmid: 12420296
references.citation: Acta Biochim Pol. 2004;51(4):1023-38
references.pmid: 15625574
references.citation: Regul Pept. 2002 Nov 15;109(1-3):115-25
references.pmid: 12409223
references.citation: Neuroscience. 2008 Aug 13;155(2):387-402
references.pmid: 18590802
references.citation: Endocrinology. 2000 Mar;141(3):1158-67
references.pmid: 10698193
references.citation: Cell Tissue Res. 1998 Jan;291(1):65-79
references.pmid: 9394044
references.citation: Dev Neurosci. 2002;24(1):14-23
references.pmid: 12145407
references.citation: Mol Cell Endocrinol. 2008 Jan 2;280(1-2):13-9
references.pmid: 17945412
references.citation: Peptides. 2005 Nov;26(11):2344-50
references.pmid: 15927304
references.citation: Ann N Y Acad Sci. 2006 Jul;1070:348-53
references.pmid: 16888190
references.citation: J Neurosci Res. 2002 Mar 1;67(5):566-73
references.pmid: 11891769
references.citation: Comp Biochem Physiol C Toxicol Pharmacol. 2001 May;129(1):25-34
references.pmid: 11369298
references.citation: Peptides. 2007 Sep;28(9):1680-7
references.pmid: 17467121
references.citation: J Mol Neurosci. 2003 Apr;20(2):141-52
references.pmid: 12794308
references.citation: Cancer Res. 1995 Nov 1;55(21):4886-91
references.pmid: 7585525
references.citation: Curr Pharm Des. 2004;10(23):2861-89
references.pmid: 15379674
references.citation: Gen Comp Endocrinol. 2007 Aug-Sep;153(1-3):115-23
references.pmid: 17270184
references.citation: Peptides. 2007 Sep;28(9):1797-804
references.pmid: 17601637
references.citation: Ann N Y Acad Sci. 2009 Apr;1163:353-7
references.pmid: 19456358
references.citation: Br J Pharmacol. 2003 Jul;139(5):1050-8
references.pmid: 12839880
references.citation: J Biochem Biophys Methods. 2004 Oct 29;61(1-2):189-98
references.pmid: 15560935
references.citation: Peptides. 2006 Apr;27(4):743-52
references.pmid: 16181705
references.citation: Pharmacol Rev. 2009 Sep;61(3):283-357
references.pmid: 19805477
references.citation: Regul Pept. 2002 Nov 15;109(1-3):49-55
references.pmid: 12409214
references.citation: Am J Pathol. 1999 Dec;155(6):1893-900
references.pmid: 10595920
references.citation: J Vet Sci. 2005 Mar;6(1):1-5
references.pmid: 15785117
references.citation: J Mol Neurosci. 2010 Nov;42(3):419-27
references.pmid: 20405239
references.citation: Peptides. 2006 Jan;27(1):87-94
references.pmid: 16095757
references.citation: Mol Cell Endocrinol. 1994 Feb;99(1):31-7
references.pmid: 7514549
references.citation: Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):225-30
references.pmid: 17286974
references.citation: Neurobiol Dis. 2008 Oct;32(1):66-80
references.pmid: 18652895
references.citation: J Neuroimmunol. 2004 Apr;149(1-2):167-81
references.pmid: 15020077
references.citation: Cancer Res. 2006 Sep 1;66(17):8796-803
references.pmid: 16951196
references.citation: Ann N Y Acad Sci. 2000;921:400-4
references.pmid: 11193864
references.citation: Reprod Toxicol. 2001 May-Jun;15(3):253-60
references.pmid: 11390169
references.citation: Regul Pept. 2002 Nov 15;109(1-3):45-8
references.pmid: 12409213
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4758-63
references.pmid: 11296303
references.citation: Brain Res. 2008 Nov 19;1241:29-35
references.pmid: 18835258